Xandra Owens Breakefield, Ph.D.
This page shows the publications co-authored by Xandra Breakefield and Robert Martuza.
Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 2007 May; 14(5):460-7.
Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther. 2006 Jan; 17(1):20-30.
An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg. 1993 Jul; 79(1):104-10.
Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res. 1992 Nov; 33(3):493-503.
Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991 Jun; 3(6):608-14.
Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res. 1990 Nov; 27(3):427-39.
Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol. 1990 Aug; 2(8):739-46.
Glial growth factor-like activity in Schwann cell tumors. Ann Neurol. 1986 Sep; 20(3):317-22.
Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Exp Neurol. 1992 Mar; 115(3):303-16.
Models for inherited susceptibility to cancer in the nervous system: a molecular-genetic approach to neurofibromatosis. Dev Neurosci. 1987; 9(3):144-53.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.